PharmGen Science, Inc. (004720.KS)
KRW 4035.0
(0.62%)
KRW 4035.0
(0.62%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 5.72 Billion KRW | -91.83% |
| 2022 | 70.05 Billion KRW | 115.79% |
| 2021 | 32.46 Billion KRW | 252.04% |
| 2020 | 9.22 Billion KRW | 3807.78% |
| 2019 | 235.99 Million KRW | -94.72% |
| 2018 | 4.46 Billion KRW | 3.43% |
| 2017 | 4.31 Billion KRW | 25.14% |
| 2016 | 3.45 Billion KRW | 66.99% |
| 2015 | 2.06 Billion KRW | 145.1% |
| 2014 | -4.58 Billion KRW | -23.93% |
| 2013 | -3.69 Billion KRW | 29.3% |
| 2012 | -5.23 Billion KRW | 40.71% |
| 2011 | -8.82 Billion KRW | -219.05% |
| 2010 | -2.76 Billion KRW | -42.06% |
| 2009 | -1.94 Billion KRW | 82.8% |
| 2008 | -11.31 Billion KRW | -5000.82% |
| 2007 | -221.83 Million KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.05 Billion KRW | -46.09% |
| 2024 Q1 | 1.94 Billion KRW | 706.63% |
| 2023 Q4 | -321.13 Million KRW | 84.86% |
| 2023 Q1 | 1.46 Billion KRW | 214.73% |
| 2023 Q2 | 6.7 Billion KRW | 357.4% |
| 2023 Q3 | -2.12 Billion KRW | -131.64% |
| 2023 FY | 5.72 Billion KRW | -91.83% |
| 2022 Q4 | -1.27 Billion KRW | -249.04% |
| 2022 Q3 | 857.13 Million KRW | -93.16% |
| 2022 Q2 | 12.53 Billion KRW | -78.36% |
| 2022 Q1 | 57.94 Billion KRW | 336.42% |
| 2022 FY | 70.05 Billion KRW | 115.79% |
| 2021 Q3 | 3.75 Billion KRW | 154.21% |
| 2021 Q2 | -6.92 Billion KRW | -130.95% |
| 2021 Q1 | 22.35 Billion KRW | 255.2% |
| 2021 FY | 32.46 Billion KRW | 252.04% |
| 2021 Q4 | 13.27 Billion KRW | 253.93% |
| 2020 Q2 | 1.57 Billion KRW | 238.6% |
| 2020 FY | 9.22 Billion KRW | 3807.78% |
| 2020 Q4 | 6.29 Billion KRW | 153.02% |
| 2020 Q3 | 2.48 Billion KRW | 57.53% |
| 2020 Q1 | -1.13 Billion KRW | -57.04% |
| 2019 Q4 | -725.53 Million KRW | -397.06% |
| 2019 Q2 | 655.76 Million KRW | 26.67% |
| 2019 FY | 235.99 Million KRW | -94.72% |
| 2019 Q1 | 517.71 Million KRW | -60.04% |
| 2019 Q3 | -145.96 Million KRW | -122.26% |
| 2018 Q4 | 1.29 Billion KRW | 433.38% |
| 2018 FY | 4.46 Billion KRW | 3.43% |
| 2018 Q2 | 2.01 Billion KRW | 121.89% |
| 2018 Q3 | 242.91 Million KRW | -87.97% |
| 2018 Q1 | 910.06 Million KRW | 11.43% |
| 2017 Q2 | 1.26 Billion KRW | 75.5% |
| 2017 FY | 4.31 Billion KRW | 25.14% |
| 2017 Q4 | 816.67 Million KRW | -46.3% |
| 2017 Q3 | 1.52 Billion KRW | 20.44% |
| 2017 Q1 | 719.52 Million KRW | -47.33% |
| 2016 Q1 | 1.53 Billion KRW | 107001.26% |
| 2016 Q3 | 462.51 Million KRW | 415.47% |
| 2016 Q4 | 1.36 Billion KRW | 195.39% |
| 2016 Q2 | 89.72 Million KRW | -94.15% |
| 2016 FY | 3.45 Billion KRW | 66.99% |
| 2015 Q4 | 1.43 Million KRW | 100.11% |
| 2015 FY | 2.06 Billion KRW | 145.1% |
| 2015 Q3 | -1.25 Billion KRW | -165.31% |
| 2015 Q2 | 1.92 Billion KRW | 37.48% |
| 2015 Q1 | 1.39 Billion KRW | 155.39% |
| 2014 Q3 | -998.83 Million KRW | -108.68% |
| 2014 Q2 | -478.65 Million KRW | 17.61% |
| 2014 FY | -4.58 Billion KRW | -23.93% |
| 2014 Q1 | -580.95 Million KRW | 74.39% |
| 2014 Q4 | -2.52 Billion KRW | -152.82% |
| 2013 Q3 | -987.94 Million KRW | -1505.51% |
| 2013 Q4 | -2.26 Billion KRW | -129.58% |
| 2013 FY | -3.69 Billion KRW | 29.3% |
| 2013 Q1 | -512.78 Million KRW | 90.11% |
| 2013 Q2 | 70.29 Million KRW | 113.71% |
| 2012 Q4 | -5.18 Billion KRW | -1591.87% |
| 2012 FY | -5.23 Billion KRW | 40.71% |
| 2012 Q2 | -649.8 Million KRW | -171.85% |
| 2012 Q3 | -306.34 Million KRW | 52.86% |
| 2012 Q1 | 904.42 Million KRW | 128.9% |
| 2011 Q1 | 1.01 Billion KRW | 126.75% |
| 2011 Q4 | -3.12 Billion KRW | -555.81% |
| 2011 FY | -8.82 Billion KRW | -219.05% |
| 2011 Q2 | -7.56 Billion KRW | -848.18% |
| 2011 Q3 | 686.67 Million KRW | 109.07% |
| 2010 Q3 | 274.29 Million KRW | -54.61% |
| 2010 Q2 | 604.26 Million KRW | 344.01% |
| 2010 Q1 | 136.09 Million KRW | 150.58% |
| 2010 FY | -2.76 Billion KRW | -42.06% |
| 2010 Q4 | -3.78 Billion KRW | -1478.21% |
| 2009 Q2 | -1.77 Billion KRW | -93.43% |
| 2009 Q4 | -269.08 Million KRW | -126.36% |
| 2009 Q3 | 1.02 Billion KRW | 157.39% |
| 2009 Q1 | -919.69 Million KRW | 92.83% |
| 2009 FY | -1.94 Billion KRW | 82.8% |
| 2008 Q1 | 1.75 Billion KRW | 360.68% |
| 2008 Q3 | 596.64 Million KRW | 171.83% |
| 2008 Q4 | -12.83 Billion KRW | -2251.19% |
| 2008 FY | -11.31 Billion KRW | -5000.82% |
| 2008 Q2 | -830.61 Million KRW | -147.37% |
| 2007 Q4 | -672.67 Million KRW | 41.41% |
| 2007 Q2 | 201.79 Million KRW | -85.56% |
| 2007 FY | -221.83 Million KRW | 0.0% |
| 2007 Q3 | -1.14 Billion KRW | -668.92% |
| 2007 Q1 | 1.39 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Daewoong Co., Ltd. | 152.66 Billion KRW | 96.248% |
| Wooridul Huebrain Limited | -14.54 Billion KRW | 139.389% |